Sarepta Therapeutics (NASDAQ:SRPT) Given New $182.00 Price Target at Piper Sandler

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective lowered by Piper Sandler from $200.00 to $182.00 in a research report released on Wednesday,Benzinga reports. Piper Sandler currently has an overweight rating on the biotechnology company’s stock.

A number of other research firms also recently weighed in on SRPT. Barclays decreased their price target on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Raymond James restated an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Stock Down 3.3 %

NASDAQ:SRPT opened at $133.34 on Wednesday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a market cap of $12.74 billion, a PE ratio of 106.67 and a beta of 0.81. Sarepta Therapeutics has a 52-week low of $78.67 and a 52-week high of $173.25. The stock has a 50-day simple moving average of $122.50 and a 200 day simple moving average of $131.49.

Institutional Trading of Sarepta Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Innealta Capital LLC acquired a new stake in Sarepta Therapeutics during the 2nd quarter worth approximately $31,000. New Covenant Trust Company N.A. acquired a new stake in Sarepta Therapeutics during the 1st quarter worth approximately $32,000. Sunbelt Securities Inc. lifted its holdings in Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares during the last quarter. Huntington National Bank increased its stake in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 175 shares during the period. Finally, Nkcfo LLC bought a new position in Sarepta Therapeutics during the 2nd quarter worth $43,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.